Ampio Stock Analysis

AMPE
 Stock
  

USD 0.40  0.02  5.26%   

The big decline in price over the last few months for Ampio Pharm could raise concerns from shareholders as the firm is trading at a share price of 0.4 on 121,999 in volume. The company executives failed to add value to investors and position the firm supply of money to exploit market volatility in November. However, diversifying your holdings with Ampio Pharm or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 12.97. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Ampio Pharm partners.
Please continue to Trending Equities.
  
The Ampio Pharm stock analysis report makes it easy to digest most publicly released information about Ampio Pharm and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Ampio Stock analysis module also helps to analyze the Ampio Pharm price relationship with some important fundamental indicators such as market cap and management efficiency.

Ampio Stock Analysis Notes

About 13.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Ampio Pharm recorded a loss per share of 0.12. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 10th of November 2022. Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19 and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Ampio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 18 people. For more info on Ampio Pharm please contact Michael Martino at 720 437 6500 or go to https://www.ampiopharma.com.

Ampio Pharm Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ampio Pharm's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ampio Pharm or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ampio Pharm generated a negative expected return over the last 90 days
Ampio Pharm has high historical volatility and very poor performance
Ampio Pharm has some characteristics of a very speculative penny stock
Net Loss for the year was (17.07 M) with profit before overhead, payroll, taxes, and interest of 0.
Ampio Pharm currently holds about 23.25 M in cash with (14.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1.
Ampio Pharm has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc. - BioSpace

Ampio Pharm Upcoming and Recent Events

Earnings reports are used by Ampio Pharm to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ampio Pharm previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report2nd of March 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End2nd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Ampio Largest EPS Surprises

Earnings surprises can significantly impact Ampio Pharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-09
2022-06-30-0.02-0.010.0150 
2021-03-03
2020-12-31-0.02-0.010.0150 
2019-11-07
2019-09-30-0.04-0.05-0.0125 
View All Earnings Estimates

Ampio Pharm SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Ampio Pharm prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Ampio Pharm investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Ampio Pharm specific information freely available to individual and institutional investors to make a timely investment decision.
1st of September 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
12th of August 2022
Submission of Matters to a Vote of Security Holders
View
3rd of August 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Cost Associated with Exit or Disposal Activities
View
8th of July 2022
Unclassified Corporate Event
View
24th of June 2022
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
2nd of June 2022
Financial Statements and Exhibits. Other Events
View
1st of June 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
16th of May 2022
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View

Ampio Market Capitalization

The company currently falls under 'Nano-Cap' category with current market capitalization of 6.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ampio Pharm's market, we take the total number of its shares issued and multiply it by Ampio Pharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Ampio Profitablity

Ampio Pharm's profitability indicators refer to fundamental financial ratios that showcase Ampio Pharm's ability to generate income relative to its revenue or operating costs. If, let's say, Ampio Pharm is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ampio Pharm's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ampio Pharm's profitability requires more research than a typical breakdown of Ampio Pharm's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(55.48) (59.86) 
Return on Average Assets(55.35) (59.71) 
Return on Average Equity(76.23) (82.25) 
Return on Invested Capital(5.29) (5.43) 
Return on Sales(552.48) (596.09) 

Management Efficiency

The entity has return on total asset (ROA) of (0.8142) % which means that it has lost $0.8142 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (1.3071) %, meaning that it created substantial loss on money invested by shareholders. Ampio Pharm management efficiency ratios could be used to measure how well ampio pharm manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2022, Return on Investment is expected to decline to -59.86. In addition to that, Return on Average Assets is expected to decline to -59.71. Ampio Pharm Assets Non Current are projected to decrease significantly based on the last few years of reporting. The past year's Assets Non Current were at 3.19 Million. The current year Revenue to Assets is expected to grow to 0.0224, whereas Goodwill and Intangible Assets are forecasted to decline to about 732.8 K.
Last ReportedProjected for 2022
Book Value per Share 0.14  0.14 
Enterprise Value over EBIT(6.00) (6.47) 
Enterprise Value over EBITDA(6.18) (6.67) 
Price to Book Value 4.22  5.98 
Tangible Assets Book Value per Share 0.20  0.20 
Enterprise Value98.8 M137.4 M
Tangible Asset Value38.8 M32.6 M

Technical Drivers

As of the 2nd of December, Ampio Pharm shows the mean deviation of 8.12, and Risk Adjusted Performance of (0.1). Ampio Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Ampio Pharm, which can be compared to its rivals. Please confirm Ampio Pharm jensen alpha, as well as the relationship between the potential upside and skewness to decide if Ampio Pharm is priced correctly, providing market reflects its regular price of 0.4 per share. As Ampio Pharm is a penny stock we also strongly suggest to validate its total risk alpha numbers.

Ampio Pharm Price Movement Analysis

The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Triangular Moving Average shows Ampio Pharm double smoothed mean price over a specified number of previous prices (i.e., averaged twice).
.

Ampio Pharm Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ampio Pharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ampio Pharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ampio Pharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jobes Elizabeth Varki over six months ago via Macroaxis 
Acquisition by Jobes Elizabeth Varki of 150000 shares of Ampio Pharmaceuticals subject to Rule 16b-3
David BarOr over six months ago via Macroaxis 
Acquisition by David BarOr of 75000 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Holli Cherevka over six months ago via Macroaxis 
Payment of 47200 shares by Holli Cherevka of Ampio Pharmaceuticals subject to Rule 16b-3
Richard Giles over six months ago via Macroaxis 
Acquisition by Richard Giles of 75000 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Martino Michael A over a year ago via Macroaxis 
Acquisition by Martino Michael A of 750000 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Martino Michael A over a year ago via Macroaxis 
Acquisition by Martino Michael A of 150000 shares of Ampio Pharmaceuticals subject to Rule 16b-3
David BarOr over a year ago via Macroaxis 
Acquisition by David BarOr of 120000 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Philip Coelho over a year ago via Macroaxis 
Exercise or conversion by Philip Coelho of 6737 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Stokely Dan over a year ago via Macroaxis 
Exercise or conversion by Stokely Dan of 22500 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Holli Cherevka over a year ago via Macroaxis 
Exercise or conversion by Holli Cherevka of 2603 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Stokely Dan over a year ago via Macroaxis 
Exercise or conversion by Stokely Dan of 35000 shares of Ampio Pharmaceuticals subject to Rule 16b-3
Holli Cherevka over a year ago via Macroaxis 
Exercise or conversion by Holli Cherevka of 44631 shares of Ampio Pharmaceuticals subject to Rule 16b-3

Ampio Pharm Technical and Predictive Indicators

Ampio Pharm Forecast Models

Ampio Pharm time-series forecasting models is one of many Ampio Pharm's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ampio Pharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Ampio Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Ampio Pharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ampio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Ampio Pharm. By using and applying Ampio Stock analysis, traders can create a robust methodology for identifying Ampio entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 61.41  61.05 

Current Ampio Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ampio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ampio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.0Strong Buy1Odds
Ampio Pharm current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Ampio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ampio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ampio Pharm, talking to its executives and customers, or listening to Ampio conference calls.
Ampio Analyst Advice Details

Ampio Stock Analysis Indicators

Ampio Pharm stock analysis indicators help investors evaluate how Ampio Pharm stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ampio Pharm shares will generate the highest return on investment. By understating and applying Ampio Pharm stock analysis, traders can identify Ampio Pharm position entry and exit signals to maximize returns.
Begin Period Cash Flow17346000.00
Logo U R LimglogosUSAMPE.png
Common Stock Shares Outstanding11523118.20
Total Stockholder Equity27284000.00
DescriptionAmpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampi
Total Cashflows From Investing Activities-97000.00
Property Plant And Equipment Net3193000.00
Retained Earnings-217602000.00
Cash And Short Term Investments33892000.00
Retained Earnings Total Equity-217602000.00
Cash33892000.00
CodeAMPE
Accounts Payable4811000.00
50 Day M A0.1068
Total Current Liabilities925000.00
Currency CodeUSD
Non Current Assets Total3193000.00
Common Stock Total Equity23000.00
Non Currrent Assets Other629000.00
Please continue to Trending Equities. You can also try Fund Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for analysis

When running Ampio Pharm price analysis, check to measure Ampio Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ampio Pharm is operating at the current time. Most of Ampio Pharm's value examination focuses on studying past and present price action to predict the probability of Ampio Pharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Ampio Pharm's price. Additionally, you may evaluate how the addition of Ampio Pharm to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is Ampio Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ampio Pharm. If investors know Ampio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ampio Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
6.2 M
Return On Assets
(0.81) 
Return On Equity
(1.31) 
The market value of Ampio Pharm is measured differently than its book value, which is the value of Ampio that is recorded on the company's balance sheet. Investors also form their own opinion of Ampio Pharm's value that differs from its market value or its book value, called intrinsic value, which is Ampio Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ampio Pharm's market value can be influenced by many factors that don't directly affect Ampio Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ampio Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Ampio Pharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ampio Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.